Latest News about BLUE
Recent news which mentions BLUE
From Benzinga
5 Stocks To Watch For March 7, 2022
March 07, 2022
From Benzinga
2 Dirt Cheap Biotechs to Buy If You're a Contrarian
March 05, 2022
From Motley Fool
2 Money-Burning Biotech Stocks to Avoid
March 01, 2022
From Motley Fool
Stocks That Hit 52-Week Lows On Thursday
February 17, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Friday
February 04, 2022
From Benzinga
2 Biotech Stocks That Could Make You Richer
February 02, 2022
From Motley Fool
FDA Pushes Review Period For Bluebird bio's Neurodegenerative Disease, Thalassemia Gene Therapies
January 18, 2022
Tickers
BLUE
From Benzinga
Why Bluebird Bio Stock Is Sinking This Week
January 14, 2022
From Motley Fool
Better Buy: CRISPR vs. Intellia
January 03, 2022
From Motley Fool
12 Health Care Stocks Moving In Wednesday's After-Market Session
December 29, 2021
From Benzinga
Mid-Day Market Update: Crude Oil Drops Over 5%; Society Pass Shares Jump
December 20, 2021
From Benzinga
38 Stocks Moving In Monday's Mid-Day Session
December 20, 2021
From Benzinga
Bluebird bio's Neurodegenerative Disease Gene Therapy Under Priority FDA Review, Despite Clinical Hold
December 20, 2021
Tickers
BLUE
From Benzinga
Could This Soaring Biotech Stock Make You Rich?
December 15, 2021
From Motley Fool
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 13, 2021
From Benzinga
From InvestorPlace
New Data At ASH21 Show Bluebird's Thalassemia Gene Therapy Potentially Curative One-Time Treatment
December 13, 2021
Tickers
BLUE
From Benzinga
Bluebird Bio Posts Updated Data From Sickle Cell Gene Therapy Program
December 13, 2021
Tickers
BLUE
From Benzinga
22 Stocks Moving in Monday's Pre-Market Session
December 13, 2021
From Benzinga
The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More
December 12, 2021
From Benzinga
2 Popular Healthcare Stocks I'd Avoid at All Costs
December 03, 2021
From Motley Fool
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 22, 2021
From Benzinga
From InvestorPlace
Bluebird Bio's Thalassemia Gene Therapy Under Priority Review With FDA
November 22, 2021
Tickers
BLUE
From Benzinga
Better Buy: Vertex Pharmaceuticals vs. CRISPR
November 20, 2021
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.